Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

Exclusion Criteria

• •Enrolled in any other treatment clinical trial.
• •Is breastfeeding.
• •Active severe or medically significant or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
• •Has human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.
• •Left ventricular ejection fraction (LVEF) less than 45% or symptomatic cardiac disease, or myocardial infarction within the past 6 months.
• •Previous treatment with complete cumulative doses of doxorubicin or other anthracyclines.
• •Baseline, moderate, peripheral neuropathy or patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
• •Post auto or allo stem cell transplant (SCT).
• •Cerebral/meningeal disease related to the underlying malignancy.
• •History of progressive multifocal leukoencephalopathy (PML).
• •Current diagnosis of any of the following:
• •* Primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas. Cutaneous ALCL with tumor spread outside of the skin and to lymph nodes away from the primary site are eligible.